← SynDRA
GALETERONE
SynDRA canonical compound SYN0031599 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | AR | CYP17A1 |
| Mechanism of action | androgen receptor modulator |
All known targets
Mechanisms of action (all sources)
- AR ANTAGONIST
- CYP17A1 INHIBITOR
- Cytochrome P450 17A1 inhibitor
- AR MODULATOR
- AR INHIBITOR
Drug classes
Cross-references
Synonyms
- Galeterona
- TOK-001
- VN-124
- VN/124
- VN/124-1
- TOK 001
- Galaterone
- UNII-WA33E149SW
- WA33E149SW
- (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol
- (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
- Galeterone [USAN:INN]
- Galeterone (USAN)
- TOK-001(Galeterone)
- SCHEMBL939234
- GTPL8638
- 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol
- CHEMBL2105738
- Galeterone, >
- Galeterone [USAN]
- Tok-001 (galeterone)
- VN-124-1
- 3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
- (3S,8R,9S,10R,13S,14S)-17-(1H-Benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
- TOK-001; Galeterone
- GALETERONE [INN]
- GALETERONE [WHO-DD]
- Galeterone, >=98% (HPLC)
- CHEBI:177536
- (3?)-17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3-ol
- 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
- BCPP000040
- DTXSID101025602
- AMY27882
- BCP02827
- EX-A1025
- ZINC6718442
- BDBM50435990
- MFCD16660907
Look up GALETERONE in the interactive SynDRA portal →